The main characteristic of the studies included in the meta-analysis.

Cohort’s characteristics.

Network meta-analyses: PFS, OS, grade 3–5 AE in all-histology NSCLC.

Clinical outcomes of pembrolizumab monotherapy according to PD-L1 expression level.

ADC Histogram Parameters of Pathologic Grades of NSCLC.

Cytokine expression levels between NSCLC patients and healthy subjects.

Studies evaluating treatment patterns in patients with advanced non-small cell lung cancer by country.

Overall survival by NSCLC histology, predictive biomarker testing, and mutation status (EGFR mutation and/or ALK rearrangement).

Subgroup analysis of HR in overall survival (OS) by univariate and multivariable analyses.

Types of recurrence of both groups.

Baseline demographics according to mutation types among EGFR positive lung adenocarcinoma subjects.

FIR is given for experiments using C3-NucView pCLE of A549, H460, H1975, H1650 and HCC827 cell lines (in vitro) and tumor xenografts (ex vivo and in vivo). VEH: vehicle. CDDP:...

BackgroundPembrolizumab is currently approved as a first-line therapy for advanced non-small cell lung cancer (NSCLC) patients with a programed death ligand-1 (PD-L1) expression...

Basic characteristics of the retrieved studies for prognostic analysis.

Demographic and clinical characteristics of patients in the matched (n = 4,182) cohorts.

List of features of each patient whose tumors harbored EGFR TKI resistant mutations.

IntroductionComparison of the effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors (TKIs) would improve patients’ clinical benefits and save...

Mediastinal lymph-node puncture rates according to station (study Step 1).

Operative outcomes by the number of port following VATS lobectomy for non-small cell lung cancer.

PurposeThis systematic review with network meta-analysis compared the efficacy and safety of currently licensed second-line treatments in patients with late stage non-small cell...